Jacobio Pharmaceuticals completes HK$0.46 million on-market share repurchase, treasury stock rises to 7.15 million shares

Bulletin Express05-18

Jacobio Pharmaceuticals Group Co., Ltd. reported to the Hong Kong Stock Exchange that it repurchased 82,800 ordinary shares on 18 May 2026. The shares were bought on-market at prices ranging between HK$5.55 and HK$5.56, representing a volume-weighted average of HK$5.56 per share and an aggregate consideration of HK$0.46 million.

Following the transaction, Jacobio’s outstanding share count (excluding treasury shares) decreased by 0.01055% to 784.61 million, while treasury shares increased to 7.15 million. Total issued shares remained unchanged at 791.76 million because the repurchased shares were retained in treasury rather than cancelled.

The buyback forms part of a repurchase mandate approved on 10 June 2025, which authorises the company to buy back up to 78.87 million shares. Cumulatively, Jacobio has now repurchased 4.13 million shares under this mandate, equivalent to 0.52% of the company’s issued share capital at the time the authority was granted. A 30-day moratorium on new share issues or further sales of treasury shares is in effect until 17 June 2026, in line with Hong Kong listing rules.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192697463?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-18 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192697463","market":"hk","top_or_hot":-1,"title":"Jacobio Pharmaceuticals completes HK$0.46 million on-market share repurchase, treasury stock rises to 7.15 million shares","media":"Bulletin Express","content":"<p>Jacobio Pharmaceuticals Group Co., Ltd. reported to the Hong Kong Stock Exchange that it repurchased 82,800 ordinary shares on 18 May 2026. The shares were bought on-market at prices ranging between HK$5.55 and HK$5.56, representing a volume-weighted average of HK$5.56 per share and an aggregate consideration of HK$0.46 million.</p>\n<p>Following the transaction, Jacobio’s outstanding share count (excluding treasury shares) decreased by 0.01055% to 784.61 million, while treasury shares increased to 7.15 million. Total issued shares remained unchanged at 791.76 million because the repurchased shares were retained in treasury rather than cancelled.</p>\n<p>The buyback forms part of a repurchase mandate approved on 10 June 2025, which authorises the company to buy back up to 78.87 million shares. Cumulatively, Jacobio has now repurchased 4.13 million shares under this mandate, equivalent to 0.52% of the company’s issued share capital at the time the authority was granted. A 30-day moratorium on new share issues or further sales of treasury shares is in effect until 17 June 2026, in line with Hong Kong listing rules.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobio Pharmaceuticals completes HK$0.46 million on-market share repurchase, treasury stock rises to 7.15 million shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobio Pharmaceuticals completes HK$0.46 million on-market share repurchase, treasury stock rises to 7.15 million shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-18 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jacobio Pharmaceuticals Group Co., Ltd. reported to the Hong Kong Stock Exchange that it repurchased 82,800 ordinary shares on 18 May 2026. The shares were bought on-market at prices ranging between HK$5.55 and HK$5.56, representing a volume-weighted average of HK$5.56 per share and an aggregate consideration of HK$0.46 million.</p>\n<p>Following the transaction, Jacobio’s outstanding share count (excluding treasury shares) decreased by 0.01055% to 784.61 million, while treasury shares increased to 7.15 million. Total issued shares remained unchanged at 791.76 million because the repurchased shares were retained in treasury rather than cancelled.</p>\n<p>The buyback forms part of a repurchase mandate approved on 10 June 2025, which authorises the company to buy back up to 78.87 million shares. Cumulatively, Jacobio has now repurchased 4.13 million shares under this mandate, equivalent to 0.52% of the company’s issued share capital at the time the authority was granted. A 30-day moratorium on new share issues or further sales of treasury shares is in effect until 17 June 2026, in line with Hong Kong listing rules.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01167","symbol_name":"加科思-B","start_time":0,"source_url":"","article_id":"1192697463","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192697463","pubTimestamp":1779099801,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jacobio Pharmaceuticals Group Co., Ltd. reported to the Hong Kong Stock Exchange that it repurchased 82,800 ordinary shares on 18 May 2026. The shares were bought on-market at prices ranging between...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01167":"加科思-B"},"translate_title":"雅可比奥制药完成0.46万港元场内股份回购库存股升至715万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1},"content_text":"Jacobio Pharmaceuticals Group Co., Ltd. reported to the Hong Kong Stock Exchange that it repurchased 82,800 ordinary shares on 18 May 2026. The shares were bought on-market at prices ranging between HK$5.55 and HK$5.56, representing a volume-weighted average of HK$5.56 per share and an aggregate consideration of HK$0.46 million.\nFollowing the transaction, Jacobio’s outstanding share count (excluding treasury shares) decreased by 0.01055% to 784.61 million, while treasury shares increased to 7.15 million. Total issued shares remained unchanged at 791.76 million because the repurchased shares were retained in treasury rather than cancelled.\nThe buyback forms part of a repurchase mandate approved on 10 June 2025, which authorises the company to buy back up to 78.87 million shares. Cumulatively, Jacobio has now repurchased 4.13 million shares under this mandate, equivalent to 0.52% of the company’s issued share capital at the time the authority was granted. A 30-day moratorium on new share issues or further sales of treasury shares is in effect until 17 June 2026, in line with Hong Kong listing rules.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192697463","isCrawlerRequest":true}